[Biological therapies in the treatment of ankylosing spondylitis: a comparison of efficacy and safety between different biological inhibitors of tumour necrosis factor-alpha]
Castillo Muñoz MA, Marín Gil R, Ubago Pérez R, Beltrán Calvo C, Flores Moreno S, Rodríguez López R
Record ID 32013000744
Authors' objectives: To compare the efficacy and safety of different anti-TNF in adult patients with active AS who are naïve to biological therapies.
Authors' recomendations: In adult patients with active AS, no significant differences are observed between the efficacy of treatments with infliximab, etanercept, adalimumab, and golimumab in terms of BASDAI50 index and ASAS20 results. There are no significant differences in safety between the four anti-TNF in terms of the incidence of severe infections and withdrawals of treatment due to adverse effects.
Project Status: Completed
URL for project: https://www.aetsa.org/publicacion/terapias-biologicas-en-el-tratamiento-de-la-espondilitis-anquilosante-eficacia-y-seguridad-comparada-entre-los-diferentes-agentes-biologicos-inhibidores-del-factor-de-necrosis-tumoral-alfa/
Year Published: 2013
URL for published report: https://www.aetsa.org/download/publicaciones/antiguas/AETSA_5_2013_Biologicos_Espondilitis.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Tumor Necrosis Factor-alpha
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.